Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoadjuvant Operable Breast Cancer × Cyclophosphamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 211 Lymphoma 203 Precursor Cell Lymphoblastic Leukemia-Lymphoma 164 Leukemia 154 Lymphoma, Large B-Cell, Diffuse 144 Multiple Myeloma 143 Lymphoma, Non-Hodgkin 129 Leukemia, Lymphocytic, Chronic, B-Cell 129 Leukemia, Myeloid, Acute 116 Lymphoma, Follicular 102 Myelodysplastic Syndromes 101 Hodgkin Disease 101 Burkitt Lymphoma 97 Lymphoma, Mantle-Cell 91 Lymphoma, B-Cell, Marginal Zone 69 Lymphoma, Large-Cell, Immunoblastic 60 Neoplasms, Plasma Cell 54 Recurrence 53 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 46 Dendritic Cell Sarcoma, Interdigitating 45 Myeloproliferative Disorders 43 Leukemia, Myeloid, Chronic-Phase 43 Leukemia, Myelomonocytic, Chronic 41 Leukemia, Myeloid, Accelerated Phase 41 Melanoma 40 Neoplasms 39 Waldenstrom Macroglobulinemia 36 Triple Negative Breast Neoplasms 34 Blast Crisis 34 Hematologic Neoplasms 33

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡